{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:42:21Z","timestamp":1781592141115,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Perpetual Trustees, Australia"},{"name":"King Saud bin Abdulaziz University-Health Sciences"},{"DOI":"10.13039\/501100002385","name":"Ministry of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.thromres.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,7,31]],"date-time":"2016-07-31T09:27:22Z","timestamp":1469957242000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state"],"prefix":"10.1016","volume":"145","author":[{"given":"Naif","family":"Alhawiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate L.","family":"Burbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith A.","family":"Kwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy J.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Shuttleworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Alzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Hamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise E.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2016.07.019_bb0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2003.08.055","article-title":"STI-571:an anticancer protein-tyrosine kinases inhibitor","volume":"309","author":"Roskoski","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.thromres.2016.07.019_bb0010","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated chronic myeloid leukaemia: results of a phase II study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2016.07.019_bb0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.thromres.2016.07.019_bb0020","first-page":"281","article-title":"Dasatinib in chronic myeloid leukaemia: a review","volume":"5","author":"Aguilera","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.thromres.2016.07.019_bb0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/10428190903518295","article-title":"Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukaemia: translating preclinical findings to clinical practice","volume":"51","author":"DeAngelo","year":"2010","journal-title":"Leukaemia and Lymphoma"},{"issue":"15","key":"10.1016\/j.thromres.2016.07.019_bb0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter","year":"2013","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.thromres.2016.07.019_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.thromres.2016.07.019_bb0040","doi-asserted-by":"crossref","first-page":"610611","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukaemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.thromres.2016.07.019_bb0045","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"Journal of National Cancer Institute"},{"issue":"10","key":"10.1016\/j.thromres.2016.07.019_bb0050","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase: ENESTnd 3year follow up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukaemia"},{"issue":"32","key":"10.1016\/j.thromres.2016.07.019_bb0055","doi-asserted-by":"crossref","first-page":"33944","DOI":"10.18632\/oncotarget.5580","article-title":"Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukaemia patients: a real clinical problem?","volume":"6","author":"Iurlo","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.thromres.2016.07.019_bb0060","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with Bcr-Abl1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.07.019_bb0065","article-title":"Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukaemia patients: new insight?","author":"Bocchia","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.thromres.2016.07.019_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood.V122.21.257.257","article-title":"Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML","volume":"122","author":"Albrecht-Schgoer","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.thromres.2016.07.019_bb0075","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood-2014-04-569707","article-title":"CEACAM2 negatively regulates hemi (ITAM-bearing) GPVI and CLEC-2 pathways and thrombus growth in vitro and in vivo","volume":"124","author":"Alshahrani","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2016.07.019_bb0080","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1182\/blood-2005-03-0911","article-title":"The Ig-ITIM superfamily member PECAM-1 regulates the \u201coutside-in\u201d signalling properties of integrin \u03b1IIb\u03b23 in platelets","volume":"106","author":"Wee","year":"2005","journal-title":"Blood"},{"issue":"51","key":"10.1016\/j.thromres.2016.07.019_bb0085","doi-asserted-by":"crossref","first-page":"36241","DOI":"10.1074\/jbc.274.51.36241","article-title":"The von Willebrand factor-glycoprotein Ib\/V\/IX interaction induces actin polymerization and cytoskeletal reorganization in rolling platelets and glycoprotein Ib\/V\/IX-transfected cells","volume":"274","author":"Yuan","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.thromres.2016.07.019_bb0090","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1074\/jbc.272.11.6986","volume":"272","author":"Jackson","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.thromres.2016.07.019_bb0095","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2006-02-004267","article-title":"Impaired \u201coutside-in\u201d integrin \u03b1IIb\u03b23 signaling and thrombus stability in TSSC6-deficient mice","volume":"108","author":"Goschnick","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2016.07.019_bb0100","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2008-06-165043","article-title":"CEACAM1 negatively regulates platelet-collagen interactions and thrombus growth in vitro and in vivo","volume":"113","author":"Wong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.07.019_bb0105","first-page":"953","article-title":"Vitronectin inhibits the thrombotic response to arterial injury in mice","volume":"98","author":"Fay","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2016.07.019_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH08-03-0141","article-title":"Assessment of thrombin generation II: validation of the calibrated automated thrombogram in platelet-poor plasma in a clinical laboratory","volume":"100","author":"Henri","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2016.07.019_bb0115","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1182\/blood-2009-02-205328","article-title":"The new tyrosine kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo","volume":"114","author":"Gratacap","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2016.07.019_bb0120","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.2515","article-title":"Arterial thrombosis-insidious, unpredictable and deadly","volume":"17","author":"Jackson","year":"2011","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.thromres.2016.07.019_bb0125","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3109\/09537104.2012.690113","article-title":"Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis","volume":"24","author":"Fuentes","year":"2012","journal-title":"Platelets"},{"issue":"7","key":"10.1016\/j.thromres.2016.07.019_bb0130","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2002-07-2209","article-title":"Platelet P-selectin facilitates atherosclerotic lesion development","volume":"101","author":"Burger","year":"2003","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2016.07.019_bb0135","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ehj.2003.08.021","article-title":"The adhesion molecule P-selectin and cardiovascular disease","volume":"24","author":"Blann","year":"2003","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.thromres.2016.07.019_bb0140","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00001721-200012000-00005","article-title":"P-selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease","volume":"11","author":"Zeiger","year":"2000","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/j.thromres.2016.07.019_bb0145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.103.4.491","article-title":"Soluble P-selectin and the risk of future cardiovascular events","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2016.07.019_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.RES.0000199295.14073.69","article-title":"Raised plasma soluble P-selectin in peripheral arterial occlusive disease enhances leukocyte adhesion","volume":"98","author":"Woollard","year":"2006","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.thromres.2016.07.019_bb0155","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jacc.2003.12.055","article-title":"Release of soluble CD40L from platelets is regulated by glycoprotein IIb\/IIIa and actin polymerisation","volume":"43","author":"Furman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.thromres.2016.07.019_bb0160","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.CIR.100.6.614","article-title":"Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes","volume":"100","author":"Aukrust","year":"1999","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.thromres.2016.07.019_bb0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00001721-200011020-00008","article-title":"Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease","volume":"11","author":"Tsakiris","year":"2000","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"9","key":"10.1016\/j.thromres.2016.07.019_bb0170","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1161\/01.RES.0000074030.98009.FF","article-title":"CD40-CD40L and platelet function: beyond hemostasis","volume":"92","author":"Freedman","year":"2003","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.thromres.2016.07.019_bb0175","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s000110050618","article-title":"Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease","volume":"49","author":"Fagerstam","year":"2000","journal-title":"Inflammation research: official journal of European Histamine Research Society"},{"issue":"24","key":"10.1016\/j.thromres.2016.07.019_bb0180","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1161\/01.CIR.0000019068.32280.B3","article-title":"Cardiopulmonary bypass induces release of soluble CD40 ligand","volume":"105","author":"Nannizzi-Alaimo","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2016.07.019_bb0185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1050-1738(01)00142-6","article-title":"CD40-CD40L interactions in atherosclerosis","volume":"12","author":"Lutgens","year":"2002","journal-title":"Trends in Cardiovascular Medicine"},{"issue":"16","key":"10.1016\/j.thromres.2016.07.019_bb0190","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1161\/01.CIR.0000089190.95415.9F","article-title":"New markers of inflammation and endothelial cell activation: part I","volume":"108","author":"Szmitko","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2016.07.019_bb0195","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.ATV.20.2.410","article-title":"Expression of tumor necrosis factor-alpha in cultured human endothelial cells stimulated with lipopolysaccride or interleukin-1 alpha","volume":"20","author":"Imaizumi","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2016.07.019_bb0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1749-6632.1989.tb24030.x","article-title":"Human endothelial cells produce IL-6","volume":"557","author":"Podor","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481630500X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938481630500X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T10:50:52Z","timestamp":1620816652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938481630500X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":40,"alternative-id":["S004938481630500X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2016.07.019","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}